Hailing from Ghana, West Africa, Charles Enyaah Amankwa holds a bachelor’s degree from Kwame Nkrumah University of Science and Technology and a master’s degree in public health from the University of Ghana, Legon. Currently, Charles Amankwa is pursuing a PhD in biomedical science at the University of North Texas Health Science Center. His current research focuses on hit-to-lead drug synthesis of novel hybrid small molecules with nitric oxide and antioxidant properties. These small molecules are hypothesized to reduce intraocular pressure and offer neuroprotection to retinal ganglion cells, as well as exert cytoprotection in trabecular meshwork cells. These molecules have shown promising outcomes in the treatment of glaucoma and other neurodegenerative diseases such as Alzheimer’s disease. Charles Amankwa has expertise in pharmacotherapy, nanoparticle drug formulation, cell culture, and rodent-related surgical skills on neuroprotection. He also has experience in teaching and training young students on basic scientific techniques and data analysis. He exerts a positive influence in his workplace and uses his positive attitude and tireless energy to encourage others to work hard and succeed. He is inspired by his late mother to utilize science to touch lives and provide solutions to ailing communities. His long-term goal is to delve into pharmaceutical research and, ultimately, impart knowledge to next-generation scientists as a professor in the field of visual science.